Comparing the current results to its competitors, United Therapeutics reported Revenue decrease in the 1 quarter 2026 year on year by -1.62 %, despite the revenue increase by the most of its competitors of 13.34 %, recorded in the same quarter.
United Therapeutics Corporation Net Income in the 1 quarter 2026 fell year on year by -14.68%, while most of its competitors have experienced a contraction in net income by -23.51 %.
United Therapeutics's Comment on Competition and Industry Peers
The company faces competition for its treprostinil product from generic and other branded treprostinil manufacturers. Patent expiration, patent litigation, and competition from these manufacturers could significantly impact the company's treprostinil-based product revenues, profits, and stock price. The company's intellectual property rights may not effectively prevent competitors from developing competing products, which could materially affect revenues and profits.
September 12, 2025
As the vibrant city of Amsterdam prepares to unfold its annual European Respiratory Society (ERS) Congress from September 27 to October 1, 2025, the spotlight will illuminate United Therapeutics Corporation (Nasdaq: UTHR), a company dedicated not only to innovation in pharmaceuticals but also to enhancing the quality of life for patients suffering from chronic and life-threatening respiratory diseases. United Therapeutics is poised to present a tapestry of clinical data that reflects both its robust commercial and development portfolio. Recent research findings, poised for discussion in the heart of this congress, promise to provide deeper insights into the efficacy and safety of its therapeutic offerings. T...
July 10, 2024
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, recently announced the completion of patient enrollment for the TETON 2 study. This significant milestone is part of their larger, global TETON clinical trial program aimed at evaluating the efficacy of Tyvaso (treprostinil) inhalation solution for the treatment of idiopathic pulmonary fibrosis (IPF). The TETON 2 study has successfully enrolled 597 patients, reflecting a strong interest and hope among the medical community and patients alike for more effective treatment options for this debilitating disease.Idiopathic pulmonary fibrosis is a chronic, progressive lung disease ch...
Mira Pharmaceuticals Inc's business model is focused on the development and sale of pharmaceutical products, with a particular emphasis on research and innovation in the healthcare industry.
Medicure Inc operates as a pharmaceutical company with a business model that focuses on the research, development, and commercialization of innovative cardiovascular and other specialty pharmaceuticals. They aim to address unmet medical needs, improve patient outcomes, and deliver value to healthcare providers and consumers.
Sources:
United Therapeutics Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on United Therapeutics Corporation versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
